Asymchem (06821): Backlog growth and expanding capacity support Asymchem's FY26 delivery and multi-year CDMO growth visibility

Overview

This conference takeaway assesses how Asymchem's expanding backlog, exposure to emerging CDMO modalities and capacity investment support FY26 execution and growth beyond 2026. Goldman Sachs sees strong underlying momentum but notes potential near-term margin variability and several operating and external risks.

Core views

Goldman Sachs argues that order momentum provides substantial visibility for FY26 delivery and growth beyond the traditional one-year backlog cycle. Newly signed orders increased 54.6% YoY, while backlog rose 53.8% YoY to US$1.67bn at the time of the 1H report. Management reiterated FY26 revenue-growth guidance of 19–22%. The anticipated conversion profile—about 40% in 2H26, around 45% in 2027 and the remaining 15% in 2028—means the backlog supports a multi-year revenue path rather than merely a near-term catch-up. Emerging modalities are the principal source of order growth. Chemical macromolecules backlog grew 163.5% YoY, supported by peptides, oligonucleotides and ADC payload/linker demand; overseas orders represented 68.3% of this backlog. Biologics backlog rose 88.7% YoY, with overseas orders accounting for nearly half. The report links the growth outlook to a rising base of PPQ-stage and commercial projects: the oligonucleotide portfolio comprised 74 projects, including five PPQ, 20 late-stage clinical and 49 early-stage clinical projects, while the toxin-linker platform supported 58 projects, including three commercial, nine PPQ and 46 clinical-stage programs. Peptides are identified as a particularly attractive medium-term opportunity. Asymchem supported 60 peptide programs, including 25 obesity-related projects, eight PPQ-stage assets and one commercial project. Planned peptide capacity exceeding 69,000L by year-end, alongside continued commercial-scale supply constraints, supports management's constructive view. The report notes that commercial peptide projects typically carry materially higher order values than traditional small-molecule projects. Small molecules remain the earnings anchor despite delivery-timing delays and foreign-exchange headwinds. The business reported a 47.4% gross margin, or 49.1% at constant FX, and delivered 48 commercial projects plus 337 clinical/preclinical projects. Thirteen projects are expected to enter PPQ in 2H26, supporting continued commercialization. The company also served five small-molecule GLP-1 obesity projects, including one commercialized project and one late-stage clinical project. Capacity investment is intended to capture future demand. FY26 capex guidance was raised from the original RMB2.1bn budget to RMB2.6–2.8bn, mainly for capacity expansion and new technology platforms, and management indicated FY27 capex could exceed RMB3bn. Goldman Sachs notes that seasonally higher labor expense, share-based compensation, depreciation from newly commissioned facilities and FX could create near-term margin fluctuations, but the institution views the stronger backlog and capacity build-out as supporting the longer-term trajectory. Goldman Sachs values both listings on 25x 12-month forward P/E. Its 12-month targets are HK$168.20 for the H share and RMB185.20 for the A share; the A-share target incorporates a 20% A-H premium. The institution is Buy on Asymchem H and Neutral on Asymchem A.

Analysis framework

The report assesses earnings visibility through new-order growth, backlog size and the timing of backlog conversion. It then evaluates the modality mix, project-stage pipeline, overseas demand, capacity plans, small-molecule profitability and near-term cost pressures before applying a 12-month forward P/E valuation to each listing.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  12-month forward P/E valuation

  Goldman Sachs applies a 25x 12-month forward P/E multiple to derive the H- and A-share target prices; the A-share target also reflects a 20% A-H premium.

• Industry AnalysisSupply-demand framework

  Capacity expansion and commercial-scale peptide supply constraints

  The report relates demand for emerging modalities to available production capacity, using planned peptide expansion and supply constraints to explain the medium-term opportunity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Asymchem (H) (6821.HK)

  Primary covered H-share listing; Goldman Sachs is Buy.

  Strengths

  Strong order growth, a US$1.67bn backlog, rapid growth in chemical macromolecules and biologics, and expanding capacity.

  Weaknesses

  Near-term margins may fluctuate due to labor costs, share-based compensation, depreciation and FX.

  Comparison

  Target is HK$168.20, implying 6.9% upside from HK$157.30 as of 23 Sep 2026 close.

  Risks

  Key-client concentration, competition-driven pricing pressure, regulation and biotech-financing weakness, labor and retention challenges, and geopolitical uncertainty.

• Asymchem (A) (002821.SZ)

  Primary covered A-share listing; Goldman Sachs is Neutral.

  Strengths

  Shares the company's backlog strength, emerging-modality exposure and capacity expansion.

  Weaknesses

  Near-term margin fluctuations and the same operating and external risks apply.

  Comparison

  Target is RMB185.20, derived using a 20% A-H premium and implying 1.5% downside from RMB188.01 as of 23 Sep 2026 close.

  Risks

  Key-client concentration, competition-driven pricing pressure, regulation and biotech-financing weakness, labor and retention challenges, and geopolitical uncertainty.

Key data

• Newly signed orders+54.6% YoYSupports FY26 earnings visibility.
• BacklogUS$1.67bn; +53.8% YoYAt the date of the 1H report.
• Backlog conversion~40% in 2H26, ~45% in 2027, ~15% in 2028Extends visibility across multiple years.
• FY26 revenue-growth guidance19–22%Reiterated by management.
• Chemical macromolecules backlog growth+163.5% YoYOverseas orders were 68.3% of total backlog.
• Biologics backlog growth+88.7% YoYOverseas orders accounted for nearly half of total backlog.
• Small-molecule gross margin47.4%; 49.1% at constant FXReported despite delivery-timing and FX headwinds.
• FY26 capex guidanceRMB2.6–2.8bnRaised from the original RMB2.1bn budget; FY27 capex may exceed RMB3bn.
• H-share target priceHK$168.20Based on 25x 12-month forward P/E; 6.9% upside from HK$157.30.
• A-share target priceRMB185.20Based on 25x 12-month forward P/E and a 20% A-H premium; 1.5% downside from RMB188.01.

Impact & implications

The report indicates that a growing backlog and a later conversion schedule can support Asymchem's FY26 guidance and extend revenue visibility into 2027–28. Emerging modalities and capacity additions are positioned as longer-term growth drivers, while cost, depreciation and FX factors may affect margins in the nearer term.

Risks

• Loss of key clients could reduce orders and backlog conversion.
• Domestic and global competition could create pricing pressure.
• Regulatory risk and a downturn in biotech financing could weaken demand.
• Rising labor costs and talent-retention challenges could pressure profitability.
• Geopolitical uncertainty could affect operations or demand.

What to watch

• Progress against management's reiterated 19–22% FY26 revenue-growth guidance.
• Conversion of the backlog into 2H26, 2027 and 2028 revenue.
• Growth in chemical macromolecules, biologics, peptides, oligonucleotides and ADC-related projects.
• The number of PPQ-stage and commercial projects across emerging modalities.
• Execution of FY26 capex of RMB2.6–2.8bn and the potential for FY27 capex above RMB3bn.
• Margin effects from labor costs, share-based compensation, facility depreciation and FX.